Progress of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of operable non-small cell lung cancer / 肿瘤研究与临床
Cancer Research and Clinic
; (6): 476-480, 2023.
Article
de Zh
| WPRIM
| ID: wpr-996260
Bibliothèque responsable:
WPRO
ABSTRACT
Patients with operable non-small cell lung cancer (NSCLC) receiving neoadjuvant or adjuvant chemotherapy have a very limited improvement in 5-year survival rate. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have made a breakthrough in the treatment of EGFR-mutant advanced NSCLC, which shed light for the exploration of perioperative targeted therapy in NSCLC patients. Significant progress has been made in the research of targeted therapy of the first and third generation EGFR-TKI in perioperative patients. The availability of novel potent and less toxic targeted therapy has brought new treatments for the operable NSCLC. This article reviews the progress and existing problems of adjuvant and neoadjuvant targeted therapy in NSCLC harboring EGFR mutation.
Texte intégral:
1
Base de données:
WPRIM
Langue:
Zh
Journal:
Cancer Research and Clinic
Année:
2023
Type de document:
Article